About 1,513 results

ALLMedicine™ Giant Cell Tumor Center

Research & Reviews  548 results

Resection and reconstruction of huge tumors in the chest wall.
Journal of Cardiothoracic Surgery; Dai Z, Maihemuti M et. al.

May 14th, 2022 - To evaluate the experience and effects of resection and reconstruction of 4 cases of huge tumors in the chest wall. The clinical data of 4 patients with huge tumors in the chest wall from July 2015 to January 2020 were collected and analyzed. Ther...

Unresectable Clival Giant Cell Tumor, Tumor Control With Denosumab After Relapse: A Cas...
Journal of Pediatric Hematology/oncology; Pionelli MG, Asaftei SD et. al.

May 11th, 2022 - Giant cell tumors (GCTs) of the skull base are rare entities. Although considered histologically benign, GCTs are locally aggressive with a high rate of local recurrence. The present case describes a 14-year-old girl with a clival GCT who underwen...

Giant Cell Tumor of Bone Without Giant Cells with a Long Clinical Course: A Case Report.
International Journal of Surgical Pathology; Takase H, Kato I et. al.

May 4th, 2022 - Giant cell tumor of bone (GCTB) consists of a mixture of neoplastic mononuclear cells and non-neoplastic cells, including polynuclear giant cells. Recently, with the spread of the immunohistochemical staining marker H3.3 G34W corresponding to spec...

The relationship of preoperative hematologic parameters to invasion of anatomic structu...
Hand Surgery & Rehabilitation; Çolak TS, Özgezmez FT et. al.

Apr 27th, 2022 - Although the pathogenesis of Teno-Synovial Giant Cell Tumor (TSGCT) is not known, inflammation is thought to play a role in the etiology beside some other factors. Many researchers have found a close relationship between hematological parameters s...

see more →

Guidelines  1 results

Bone cancer.
Journal of the National Comprehensive Cancer Network : JN... Biermann JS, Adkins DR et. al.

Jun 8th, 2013 - Primary bone cancers are extremely rare neoplasms, accounting for fewer than 0.2% of all cancers. The evaluation and treatment of patients with bone cancers requires a multidisciplinary team of physicians, including musculoskeletal, medical, and r...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  7 results

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Apr 19th, 2022 - This FDA post-marketing requirement study will evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ ...

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Mar 4th, 2022 - The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Jun 22nd, 2021 - Pexidartinib is an orally administered tyrosine kinase inhibitor, currently approved in the US for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and...

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Feb 5th, 2020 - The objective of the trial is to evaluate the efficacy and safety of JMT103 in patients with GCTB that is surgically unsalvageable or for which the planned surgery is associated with severe morbidity. This study consists of two parts (phase Ib and...

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Feb 19th, 2019 - To determine how safe denosumab is in treating subjects with GCTB

see more →

News  43 results

Dr. Abraham on the Clinical Utility of Pexidartinib in TGCT

Oct 6th, 2021 - John A. Abraham, MD, FACS, founder, Orthopaedic Oncology Service, Rothman Orthopaedic Institute, and attending surgeon, Orthopaedic Surgery, Fox Chase Cancer Center, discusses the clinical utility of pexidartinib (Turalio) in tenosynovial giant ce...

Dr. Abraham on Potential Symptoms of TGCT

Oct 6th, 2021 - John A. Abraham, MD, FACS, founder, Orthopaedic Oncology Service, Rothman Orthopaedic Institute, and attending surgeon, Orthopaedic Surgery, Fox Chase Cancer Center, discusses potential symptoms of tenosynovial giant cell tumor (TGCT). TGCT can o...

Intriguing Research Brings Hope to Orthopedic Oncology

Oct 6th, 2021 - R. Lor Randall, MD, FACS The orthopedic oncology community has not seen many treatment advances due to the rarity of bone cancers, but emerging research could serve as a turning point for the specialized paradigm, explained R. Lor Randall, MD, FA...

Spotlighting Management Strategies Across Sarcoma Subtypes

Oct 6th, 2021 - Welcome to OncLive On Air™! I’m your host today, Jessica Hergert. OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital a...

Dr. Abraham on Remaining Questions With Pexidartinib in TGCT

Oct 6th, 2021 - John A. Abraham, MD, FACS, founder, Orthopaedic Oncology Service, Rothman Orthopaedic Institute, and attending surgeon, Orthopaedic Surgery, Fox Chase Cancer Center, discusses remaining questions with pexidartinib (Turalio) in tenosynovial giant c...

see more →

Patient Education  3 results see all →